For many MedTech and digital health teams, bringing software as a medical device to the European market feels less like innovation and more like navigating an increasingly complex regulatory maze. In the EU, software with a medical purpose must comply with stringent requirements under the Medical Device Regulation (MDR), covering conformity assessment, clinical evidence and post-market obligations — and the emerging EU Artificial Intelligence Act adds another layer of expectations around transparency, data governance and lifecycle monitoring for AI-related systems.
This dual regulatory landscape isn’t theoretical: it drives delays, higher costs and planning uncertainty for companies trying to scale. Many teams face simultaneous MDR conformity assessments and preparations for AI Act obligations, without clarity on how these frameworks intersect or how notified bodies will interpret them. Without a coherent strategy, development cycles are wasted on reactive fixes, compliance gaps risk failed assessments, and CE marking can be stalled indefinitely.
At Billev Pharma East, we see regulatory clarity not as a hurdle but as a strategic advantage. We help pioneers align their software as a medical device development with both MDR and AI Act expectations through structured regulatory planning, evidence generation and conformity support — enabling smoother CE marking, reduced risk and more predictable time-to-market.
What companies must do to ensure compliance for software as a medical device
Bringing software as a medical device to the EU market now requires a dual-track regulatory strategy. Compliance with the EU MDR is no longer sufficient in isolation; companies must anticipate how AI-related functionalities will be assessed under the AI Act and how both frameworks interact across the product lifecycle.
Under MDR, manufacturers must ensure correct qualification and classification, establish a compliant Quality Management System (typically aligned with ISO 13485), generate adequate clinical evidence, and define a robust post-market surveillance (PMS) system. For AI-enabled solutions, additional scrutiny applies to data integrity, performance consistency, and change management.
Integrating MDR and AI Act requirements into your software as a medical device lifecycle
To avoid costly remediation and delayed CE marking, companies should:
- Clearly define intended purpose and risk classification early.
- Align software lifecycle documentation (IEC 62304) with AI data governance requirements.
- Generate clinical and performance evidence that withstands notified body scrutiny.
- Establish transparent algorithms, validation protocols and human oversight mechanisms.
- Design post-market monitoring systems capable of tracking real-world performance and AI drift.
A fragmented approach — where MDR and AI Act compliance are handled separately — increases regulatory risk. A unified, forward-looking compliance architecture is essential to protect investment and accelerate market access.
How we help with software as a medical device compliance
At Billev Pharma East, we turn regulatory complexity into a strategic advantage for your software as a medical device development and market entry. We are a trusted, ISO-certified regulatory consultancy with over 15 years of experience helping clients navigate EU regulatory requirements across medicines, medical devices, and digital health products.
We don’t just interpret rules — we embed regulatory excellence into your product lifecycle.
What makes our support unique
- Holistic regulatory strategy – we provide ISO 13485 consulting and craft tailored compliance plans that align EU MDR, ISO 13485 and emerging AI Act expectations with your business objectives — not generic checklists.
- Deep medical device expertise – From MDR gap analysis and QMS implementation to medical device technical file preparation and notified body communication, we ensure your documentation is audit-ready and defensible.
- Collaborative partner – We work with you — not just for you — enhancing internal processes and strengthening your product’s regulatory foundation.
Whether you need support with MDR conformity assessment, ISO 13485 alignment, AI governance integration, or lifecycle documentation, our consultants streamline every step. By aligning regulatory obligations with practical implementation, we help you avoid costly rework and delays — turning compliance into an asset rather than a burden.
From early strategy planning to post-market surveillance and notified body interactions, Billev Pharma East’s bespoke support accelerates your CE marking journey and ensures sustainable, risk-based, market-ready solutions.
Turning software as a medical device compliance into competitive advantage
Regulatory pressure is increasing, but so is regulatory differentiation. Companies that proactively structure their software as a medical device development around MDR and AI Act alignment gain more than approval — they gain credibility with regulators, partners, and investors.
A well-prepared medical device technical file, transparent AI governance, and defensible clinical evidence reduce uncertainty during conformity assessment. More importantly, they create internal confidence: product updates can be managed without fear of regulatory setbacks, and scaling across EU markets becomes strategically controlled rather than reactive.
In an environment where notified bodies apply heightened scrutiny and AI oversight is evolving, waiting for clarification is not a strategy. Early integration, structured documentation, and expert regulatory guidance determine whether your CE marking becomes a milestone — or a bottleneck.
With the right partner, compliance becomes a growth enabler, not a constraint.
Read also:
Sources: 1 – European Health Commission / MDCG. (2025). Interplay between the Medical Devices Regulation (MDR) and the Artificial Intelligence Act (AI Act).
Image credits:
In-article images: Designed by Freepik
Hero image: Designed by Freepik